In a study that assessed whether the discontinuation of chronic RAS inhibition treatment influences COVID-19, based on the rationale that SARS-CoV-2 cell entry depends on ACE2 that can be upregulated by these drugs, it was found that discontinuation of RAS-inhibition in COVID-19 had no significant effect on the maximum severity of COVID-19. The gene discussed is ACE2; the disease is COVID-19.